LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,415,494
تعداد دریافت فایل اصل مقاله11,291,288
Babaloui, Somayyeh, Najafi, Masoud, Mozdarani, Hossein, Borhani, Samira, Jaberi, Ramin, Aghili, Mahdi. (1400). Radiosensitization of Glioma Cells by Temozolomide (TMZ): A Colony Formation Assay. سامانه مدیریت نشریات علمی, 12(1), 43-50. doi: 10.31661/jbpe.v0i0.1223
Somayyeh Babaloui; Masoud Najafi; Hossein Mozdarani; Samira Borhani; Ramin Jaberi; Mahdi Aghili. "Radiosensitization of Glioma Cells by Temozolomide (TMZ): A Colony Formation Assay". سامانه مدیریت نشریات علمی, 12, 1, 1400, 43-50. doi: 10.31661/jbpe.v0i0.1223
Babaloui, Somayyeh, Najafi, Masoud, Mozdarani, Hossein, Borhani, Samira, Jaberi, Ramin, Aghili, Mahdi. (1400). 'Radiosensitization of Glioma Cells by Temozolomide (TMZ): A Colony Formation Assay', سامانه مدیریت نشریات علمی, 12(1), pp. 43-50. doi: 10.31661/jbpe.v0i0.1223
Babaloui, Somayyeh, Najafi, Masoud, Mozdarani, Hossein, Borhani, Samira, Jaberi, Ramin, Aghili, Mahdi. Radiosensitization of Glioma Cells by Temozolomide (TMZ): A Colony Formation Assay. سامانه مدیریت نشریات علمی, 1400; 12(1): 43-50. doi: 10.31661/jbpe.v0i0.1223

Radiosensitization of Glioma Cells by Temozolomide (TMZ): A Colony Formation Assay

Journal of Biomedical Physics and Engineering
مقاله 5، دوره 12، شماره 1، اردیبهشت 2022، صفحه 43-50    اصل مقاله (979.12 K)
نوع مقاله: Original Research
شناسه دیجیتال (DOI): 10.31661/jbpe.v0i0.1223
نویسندگان
Somayyeh Babaloui1؛ Masoud Najafi2؛ Hossein Mozdarani3؛ Samira Borhani4؛ Ramin Jaberi5؛ Mahdi Aghili* 6
1PhD, Department of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2PhD, Department of Radiology and Nuclear Medicine, School of Paramedical Sciences, Kermanshah University of Medical Sciences, Kermanshah, Iran
3PhD, Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
4MSc, Department of Radiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5PhD, Radiation Oncology Research Center (RORC), Yas Radiation Oncology Center, Tehran University of Medical Sciences, Tehran, Iran
6MD, Cancer Research Center and Radiation Oncology Research Center (RORC), Iran Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
چکیده
Background: Glioblastoma is one of the most radioresistant cancers. It is suggested that combination of radiotherapy with other cancer treatment modalities may increase control of tumor. Temozolomide (TMZ) is one of the most known drugs for glioblastoma. It has shown that TMZ via induction of mutation and cell death can kill glioma cells.
Objective: In the current study, we aimed to show possible radiosensitization effect of TMZ for glioma cells. In addition, results compared to response of normal fibroblast cells to TMZ and irradiation.
Material and Methods: This is in vitro study for evaluation of the effect of TMZ and irradiation on high grade glioma cells and normal fibroblasts. The human fibroblast and glioma cells were cultured as monolayer. The cells were treated with 2000 μM TMZ, which was equal drug dose for IC50%. In addition, irradiation was done with 5Gy gamma rays. The formation of colony was observed following irradiation, treatment with TMZ, and combination both of them.
Results: The formation of colony for both glioma and fibroblast cells showed a reduction following irradiation or treatment with TMZ. Irradiation showed more toxicity compared to TMZ for glioma cells, but not fibroblast cells. Combination of TMZ and irradiation showed a significant reduction in the colony formation compared to irradiation or TMZ treatment alone.
Conclusion: This study showed that TMZ increases sensitivity of both glioma and fibroblast cells to ionizing radiation.
کلیدواژه‌ها
Temozolomide؛ Radiation؛ Glioblastoma؛ Fibroblast Cells
سایر فایل های مرتبط با مقاله
مراجع
  1. Nagaishi M, Nobusawa S, Yokoo H, Sugiura Y, Tsuda K, et al. Genetic mutations in high grade gliomas of the adult spinal cord. Brain Tumor Pathology. 2016;33(4):267-9. doi: 10.1007/s10014-016-0263-7.
  2. Delgado-López PD, Corrales-García EM. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol. 2016;18(11):1062-71. doi: 10.1007/s12094-016-1497-x. PubMed PMID: 26960561.
  3. Jahani-Asl A, Yin H, Soleimani VD, Haque T, Luchman HA, Chang NC, et al. Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. Nat Neurosci. 2016;19(6):798-806. doi: 10.1038/nn.4295. PubMed PMID: 27110918. PubMed PMCID: PMC4984527.
  4. Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376(11):1027-37. doi: 10.1056/NEJMoa1611977. PubMed PMID: 28296618.
  5. Haque W, Verma V, Butler EB, Teh BS. Addition of chemotherapy to hypofractionated radiotherapy for glioblastoma: practice patterns, outcomes, and predictors of survival. J Neurooncol. 2018;136(2):307-15. doi: 10.1007/s11060-017-2654-y. PubMed PMID: 29090416.
  6. Song G, Cheng L, Chao Y, Yang K, Liu Z. Emerging nanotechnology and advanced materials for cancer radiation therapy. Adv Mater. 2017;29(32). doi: 10.1002/adma.201700996. PubMed PMID: 28643452.
  7. Siddiqui F, Movsas B. Management of radiation toxicity in head and neck cancers. Semin Radiat Oncol. 2017;27(4):340-9. doi: 10.1016/j.semradonc.2017.04.008. PubMed PMID: 28865517.
  8. Tateishi K, Higuchi F, Miller JJ, Koerner MV, Lelic N, Shankar GM, et al. The alkylating chemotherapeutic temozolomide induces metabolic stress in IDH1-mutant cancers and potentiates NAD+ depletion–mediated cytotoxicity. Cancer Res. 2017; 77(15):4102-15. doi: 10.1158/0008-5472.CAN-16-2263. PubMed PMID: 28625978. PubMed PMCID: PMC5783559.
  9. Rao JU, Coman D, Walsh JJ, Ali MM, Huang Y, Hyder F. Temozolomide arrests glioma growth and normalizes intratumoral extracellular pH. Scientific Reports. 2017;7(1):1-6. doi: 10.1038/s41598-017-07609-7.
  10. Kumari S, Ahsan SM, Kumar JM, Kondapi AK, Rao NM. Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433). Sci Rep. 2017;7(1):6602. doi: 10.1038/s41598-017-06888-4. PubMed PMID: 28747713. PubMed PMCID: PMC5529576.
  11. Wang T, Pickard AJ, Gallo JM. Histone methylation by temozolomide; a classic DNA methylating anticancer drug. Anticancer Res. 2016;36(7):3289-99. PubMed PMID: 27354585. PubMed PMCID: PMC5349185.
  12. Borhani S, Mozdarani H, Babalui S, Bakhshandeh M, Nosrati H. In vitro radiosensitizing effects of temozolomide on U87MG cell lines of human glioblastoma multiforme. Iran J Med Sci. 2017;42(3):258-65. PubMed PMID: 28533574. PubMed PMCID: PMC5429494.
  13. Daniel P, Sabri S, Chaddad A, Meehan B, Jean-Claude B, Rak J, Abdulkarim BS. Temozolomide induced hypermutation in glioma: evolutionary mechanisms and therapeutic opportunities. Front Oncol. 2019;9:41. doi: 10.3389/fonc.2019.00041. PubMed PMID: 30778375. PubMed PMCID: PMC6369148.
  14. Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, et al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer. 2011;129(3):659-70. doi: 10.1002/ijc.26083. PubMed PMID: 21425258.
  15. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-96. doi: 10.1056/NEJMoa043330. PubMed PMID: 15758009.
  16. Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res. 2005;11(19):6767-71. doi: 10.1158/1078-0432.CCR-05-0722. PubMed PMID: 16203762.
  17. Parisi S, Corsa P, Raguso A, Perrone A, Cossa S, Munafò T, Sanpaolo G, Donno E, Clemente MA, Piombino M, Parisi F. Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review. Biomed Res Int. 2015;2015:620643. doi: 10.1155/2015/620643. PubMed PMID: 25815327. PubMed PMCID: PMC4359808.
  18. Mirimanoff RO, Gorlia T, Mason W, Van Den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006;24(16):2563-9. doi: 10.1200/JCO.2005.04.5963. PubMed PMID: 16735709.
آمار
تعداد مشاهده مقاله: 2,280
تعداد دریافت فایل اصل مقاله: 855


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب